Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs iShares Core High Dividend ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.45 (market cap $12.58B), while iShares Core High Dividend ETF trades at $28.72 (market cap $14.68B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Core High Dividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and iShares Core High Dividend ETF for 117 Days on average.
| HALO | HDV | |
|---|---|---|
Market Cap | $12.58B | $14.68B |
Volume | 2,179,278 | 2,925,562 |
Sector | Health | — |
52-Week High | $115.22 | $29.93 |
52-Week Low | $61.63 | $23.64 |
Typical Hold Time | 0 Days | 117 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HDV (iShares Core High Dividend ETF) trades at $28.73, up 1.59% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the 3% yield may not fully compensate for increased concentration risk.
The outlook remains cautiously optimistic given the bullish technical setup and sector rotation benefits, but investors face risks from heightened concentration in three sectors (62% allocation) and potential yield compression. The ETF's performance relative to peers like VYM suggests competitive positioning, though sector concentration requires monitoring for diversification adequacy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
